DNLI Analyst Ratings
Denali Therapeutics Inc. (DNLI) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $2.92B, listed on NASDAQ, employing roughly 503 people, carrying a beta of 1.02 to the broader market. Denali Therapeutics Inc. Led by Ryan J. Watts, public since 2017-12-08.
Analyst Ratings
In the October 2026 monthly count, 20 analysts rated DNLI: 2 Strong Buy, 17 Buy, 1 Hold, 0 Sell and 0 Strong Sell.
Twelve months earlier, in October 2025: 19 analysts, 3 Strong Buy, 16 Buy, 0 Hold, 0 Sell and 0 Strong Sell.
Price Targets
- Average Target
- $33.67
- Median Target
- $34.00
- High
- $41.00
- Low
- $26.00
- Targets Published, Last 12 Months
- 15
Recent Price Targets
The 5 most recent of 15 price targets published in the last 12 months.
| Date | Firm | Analyst | Target | Price When Posted |
|---|---|---|---|---|
| Aug 7, 2026 | UBS | Not named | $34.00 | $24.47 |
| Aug 7, 2026 | Robert W. Baird | Not named | $34.00 | $24.73 |
| Jul 23, 2026 | Morgan Stanley | Not named | $36.00 | $23.06 |
| Jul 13, 2026 | Wedbush | Laura Chico | $26.00 | $25.33 |
| Jun 22, 2026 | Stifel Nicolaus | Paul Mattels | $41.00 | $23.76 |
Recent Upgrades & Downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 25, 2026 | B. Riley Securities | maintain | Buy | Buy |
| Aug 7, 2026 | UBS | maintain | Buy | Buy |
| Jul 23, 2026 | Morgan Stanley | maintain | Overweight | Overweight |
| Jul 16, 2026 | Deutsche Bank | maintain | Buy | Buy |
| May 26, 2026 | Morgan Stanley | maintain | Overweight | Overweight |
Quantitative Rating
DNLI carries a model grade of C- (overall score 1 of 5), computed from six valuation and financial measures (discounted cash flow, return on equity, return on assets, debt to equity, price to earnings and price to book), each scored 1 to 5. It is not an analyst rating.
How to Read DNLI Analyst Coverage
Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.
For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.
Learn how analyst ratings is reported and how to read the data →
Frequently asked DNLI analyst ratings questions
- What is the DNLI consensus price target?
- As of the latest aggregator update, Denali Therapeutics Inc. (DNLI) carries a consensus 12-month price target of $33.67. Target ranges run from a low of $26.00 to a high of $41.00. The target is the average of the price targets published by sell-side equity analysts covering the name.
- What is the analyst rating consensus on DNLI?
- In the October 2026 monthly count, 20 analysts rated DNLI, and the distribution tilts to the Buy side: 2 Strong Buy, 17 Buy, 1 Hold, 0 Sell and 0 Strong Sell. Rating consensus moves slowly relative to price; it reflects sell-side conviction over a 12-month horizon rather than near-term momentum.
- What recent ratings actions has DNLI seen?
- The five most recent ratings actions on DNLI appear on the page above. Sell-side rating changes are watched for two reasons: an upgrade or downgrade with a meaningful target revision moves the consensus and can trigger short-term positioning shifts, and the firm-level rating cluster (multiple firms moving in the same direction within a short window) is a clearer signal than any single action. Options markets often price the implied-vol response within minutes of the announcement.
- How do analyst targets affect DNLI options pricing?
- Analyst target revisions tend to be priced in by the lit options market within minutes of publication, but persistent target drift over weeks does correlate with implied-volatility movement. Aggressive target hikes from multiple firms inside a single quarter tighten put skew (downside protection becomes cheaper relative to upside speculation); aggressive cuts widen put skew. The most actionable read is the implied-vol response in the hours after a target change, which is visible on the per-ticker volatility skew page.